The Goldman Sachs Group Issues Pessimistic Forecast for Stryker (NYSE:SYK) Stock Price
by Doug Wharley · The Cerbat GemStryker (NYSE:SYK – Get Free Report) had its target price lowered by research analysts at The Goldman Sachs Group from $403.00 to $357.00 in a research note issued to investors on Thursday,Benzinga reports. The firm presently has a “neutral” rating on the medical technology company’s stock. The Goldman Sachs Group’s price objective indicates a potential upside of 5.90% from the company’s current price.
SYK has been the topic of several other reports. Barclays reiterated an “overweight” rating and set a $469.00 target price on shares of Stryker in a report on Monday, February 2nd. Weiss Ratings reiterated a “hold (c+)” rating on shares of Stryker in a research note on Monday, December 22nd. Robert W. Baird set a $437.00 target price on shares of Stryker in a report on Friday, January 30th. Evercore set a $390.00 target price on shares of Stryker in a report on Monday, January 5th. Finally, Truist Financial cut their target price on shares of Stryker from $400.00 to $392.00 and set a “hold” rating on the stock in a report on Thursday, December 18th. Fourteen analysts have rated the stock with a Buy rating and six have issued a Hold rating to the company. Based on data from MarketBeat.com, Stryker currently has a consensus rating of “Moderate Buy” and an average price target of $423.22.
Get Our Latest Stock Report on SYK
Stryker Price Performance
NYSE SYK traded down $2.90 during trading on Thursday, reaching $337.11. 589,588 shares of the company traded hands, compared to its average volume of 2,050,740. The company has a debt-to-equity ratio of 0.66, a quick ratio of 1.21 and a current ratio of 1.89. The stock’s 50 day moving average price is $355.78 and its two-hundred day moving average price is $360.97. The company has a market cap of $129.10 billion, a price-to-earnings ratio of 40.18, a P/E/G ratio of 1.94 and a beta of 0.92. Stryker has a 1-year low of $319.32 and a 1-year high of $404.87.
Stryker (NYSE:SYK – Get Free Report) last posted its quarterly earnings data on Thursday, January 29th. The medical technology company reported $4.47 earnings per share for the quarter, beating the consensus estimate of $4.40 by $0.07. The firm had revenue of $7.17 billion during the quarter, compared to analysts’ expectations of $7.12 billion. Stryker had a net margin of 12.92% and a return on equity of 24.41%. The company’s quarterly revenue was up 11.4% compared to the same quarter last year. During the same quarter last year, the company posted $4.01 EPS. As a group, analysts anticipate that Stryker will post 13.47 EPS for the current year.
Insider Activity
In other Stryker news, Director Ronda E. Stryker sold 250,000 shares of Stryker stock in a transaction on Wednesday, February 4th. The shares were sold at an average price of $362.92, for a total value of $90,730,000.00. Following the transaction, the director directly owned 2,457,331 shares in the company, valued at approximately $891,814,566.52. The trade was a 9.23% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Corporate insiders own 5.90% of the company’s stock.
Institutional Investors Weigh In On Stryker
A number of institutional investors have recently modified their holdings of SYK. Sankala Group LLC bought a new position in shares of Stryker in the fourth quarter valued at approximately $26,000. Clayton Financial Group LLC bought a new position in Stryker in the 3rd quarter valued at approximately $26,000. Godfrey Financial Associates Inc. acquired a new stake in shares of Stryker in the 4th quarter valued at about $26,000. United Financial Planning Group LLC purchased a new stake in shares of Stryker in the third quarter valued at about $27,000. Finally, Atlas Capital Advisors Inc. purchased a new stake in shares of Stryker in the fourth quarter valued at about $27,000. Institutional investors own 77.09% of the company’s stock.
About Stryker
Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.